chloroquine has been researched along with Asymptomatic Colonization in 6 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide." | 2.66 | Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. ( Hsueh, PR; Hsueh, SC; Ko, WC; Lai, CC; Liu, YH; Wang, CY; Wang, YH; Yen, MY, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarah-Matio, EM | 1 |
| Guillochon, E | 1 |
| Nsango, SE | 1 |
| Abate, L | 1 |
| Ngou, CM | 1 |
| Bouopda, GA | 1 |
| Feufack-Donfack, LB | 1 |
| Bayibéki, AN | 1 |
| Tchioffo Tsapi, M | 1 |
| Talman, A | 1 |
| Marin-Menendez, A | 1 |
| Ayong, L | 1 |
| Claessens, A | 1 |
| Lefèvre, T | 1 |
| Berry, A | 1 |
| Morlais, I | 1 |
| Lai, CC | 1 |
| Liu, YH | 1 |
| Wang, CY | 1 |
| Wang, YH | 1 |
| Hsueh, SC | 1 |
| Yen, MY | 1 |
| Ko, WC | 1 |
| Hsueh, PR | 1 |
| Atakla, HG | 1 |
| Noudohounsi, MMUD | 1 |
| Salami, AY | 1 |
| Sacca, H | 1 |
| Houinato, AG | 1 |
| Barry, MC | 1 |
| Othon, GC | 1 |
| Adjadi, AA | 1 |
| Houinato, DS | 1 |
| Galatas, B | 1 |
| Nhamussua, L | 1 |
| Candrinho, B | 1 |
| Mabote, L | 1 |
| Cisteró, P | 1 |
| Gupta, H | 1 |
| Rabinovich, R | 1 |
| Menéndez, C | 1 |
| Macete, E | 1 |
| Saute, F | 1 |
| Mayor, A | 1 |
| Alonso, P | 1 |
| Bassat, Q | 1 |
| Aide, P | 1 |
| Golassa, L | 1 |
| Enweji, N | 1 |
| Erko, B | 1 |
| Aseffa, A | 1 |
| Swedberg, G | 1 |
| Maïga-Ascofaré, O | 1 |
| Rakotozandrindrainy, R | 1 |
| Girmann, M | 1 |
| Hahn, A | 1 |
| Randriamampionona, N | 1 |
| Poppert, S | 1 |
| May, J | 1 |
| Schwarz, NG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study[NCT04375709] | 60 participants (Anticipated) | Observational | 2020-03-15 | Recruiting | |||
| Viral Kinetics of SARS-CoV-2 in Patients in the Intensive Care Unit Undergoing Dental Procedures[NCT05311410] | 60 participants (Anticipated) | Interventional | 2021-09-20 | Recruiting | |||
| Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870] | 500 participants (Anticipated) | Observational | 2020-05-11 | Recruiting | |||
| Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults[NCT02698748] | Phase 2/Phase 3 | 75 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for chloroquine and Asymptomatic Colonization
| Article | Year |
|---|---|
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
1 trial available for chloroquine and Asymptomatic Colonization
| Article | Year |
|---|---|
In-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination Strategies.
Topics: Adult; Antimalarials; Asymptomatic Infections; Chloroquine; Drug Resistance; Humans; Malaria, Falcip | 2017 |
4 other studies available for chloroquine and Asymptomatic Colonization
| Article | Year |
|---|---|
Genetic Diversity of Plasmodium falciparum and Distribution of Antimalarial Drug Resistance Mutations in Symptomatic and Asymptomatic Infections.
Topics: Antimalarials; Asymptomatic Infections; Chloroquine; Drug Resistance; Folic Acid Antagonists; Genoty | 2022 |
COVID-19 infection in pediatric subjects: study of 36 cases in Conakry.
Topics: Adolescent; Asymptomatic Infections; Azithromycin; Child; Child, Preschool; Chloroquine; COVID-19; C | 2020 |
High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia, Ethiopia.
Topics: Asymptomatic Infections; Chloroquine; Dried Blood Spot Testing; Drug Resistance; Ethiopia; Haplotype | 2014 |
Molecular epidemiology and seroprevalence in asymptomatic Plasmodium falciparum infections of Malagasy pregnant women in the highlands.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Asymptomatic Infections; Chloroquine; Drug | 2015 |